SpectraScience: A Bolder Ventures Turnaround
Bolder Ventures led a $6 million second-chance financing initiative for SpectraScience, a Minneapolis-based R&D company originally focused on developing a photoablation laser for treating coronary artery disease using spectroscopy. While the initial project did not succeed as a viable treatment option, Bolder’s strategic guidance helped redirect the technology toward a groundbreaking new application.
Today, SpectraScience is a leader in early colorectal cancer diagnosis, offering innovative solutions that greatly improve recovery rates. Their WavSTAT Optical Biopsy System® uses light to accurately assess tissue health, instantly determining whether tissue is normal, pre-cancerous, or cancerous—eliminating the need for costly and invasive physical biopsies. SpectraScience has also partnered with MIT for advanced laser research and collaborated with the Cleveland Clinic to conduct clinical trials, further solidifying its reputation as an innovator in the fight against cancer.
